Epidermal Growth Factor Receptor-GEP100-Arf6 Axis Affects the Prognosis of Lung Adenocarcinoma
Epidermal Growth Factor Receptor-GEP100-Arf6 Axis Affects the Prognosis of Lung Adenocarcinoma
复制标题
DOI：
10.1159/000360089
复制
发表时间：
2014-01-01
期刊：
影响因子：
3.5
通讯作者：
Tanaka, Funnihiro
中科院分区：
文献类型：
--
作者：
Oka, Soichi;Uramoto, Hidetaka;Tanaka, Funnihiro
Arf6和GEP100的过表达是肿瘤侵袭活性的原因，而侵袭活性是激活表皮生长因子受体(EGFR)信号通路的关键。然而，EGFR-GEP100-Arf6轴的表达是否可以作为肺癌预后的生物标志物尚未完全确定。肿瘤标本取自182例接受肺腺癌全切除的患者。我们通过免疫组织化学分析了p-EGFR(p-EGFR)、GEP100和Arf6在原发肿瘤中的表达水平。P-EGFR表达65例(35.7%)，GEP100表达95例(52.2%)，Arf6表达20例(11.0%)。P-EGFR和GEP100的表达与血管侵袭性显著相关。这些单个分子的表达与存活率的任何统计上的显着差异无关。然而，根据多变量分析，p-EGFR、GEP100和Arf6的三重阳性表达与死亡风险的增加显著相关。EGFR-GEP100-Arf6轴影响肺腺癌患者的预后。联合检测p-EGFR、GEP100和Arf6染色可预测患者术后预后。(C)2014年S.Karger AG，巴塞尔
The overexpression of Arf6 and GEP100 is responsible for the invasive activity that is crucial for the activation of the epidermal growth factor receptor (EGFR) signaling pathways in human cancer. However, whether or not the expression of the EGFR-GEP100-Arf6 axis can be used as a biomarker for the prognosis of lung cancer has yet to be fully determined. Tumor specimens were collected from 182 patients who underwent a complete resection for lung adenocarcinoma. We analyzed phospho-EGFR (p-EGFR), GEP100, and Arf6 expression levels in the primary tumor by immunohistochemical analysis. The expression of p-EGFR,GEP100, and Arf6 was observed in 65 (35.7%), 95 (52.2%), and 20 (11.0%) patients, respectively. Significant associations between p-EGFR and GEP100 expression and vessel invasion were identified. The expression of these individual molecules was not associated with any statistically significant differences in survival. However, triple positive expression of p-EGFR, GEP100, and Arf6 was significantly associated with an increased risk of death based on the multivariate analysis. The EGFR-GEP100-Arf6 axis affected the prognosis of patients with primary lung adenocarcinoma. The combination of p-EGFR, GEP100, and Arf6 staining can predict the prognosis of patients after surgery. (C) 2014 S. Karger AG, Basel